Back to results
US 2021/0277045 A1Published application
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
AssigneeAtea Pharmaceuticals, Inc.
InventorsAdel Moussa, Jean-Pierre Sommadossi
Life of this patent
Estimating the term…
Abstract
A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
Claims36
A pharmaceutical composition comprising an effective amount of a compound of the formula:
- and an effective amount of an additional anti-viral compound selected from a protease inhibitor, a NS5B polymerase inhibitor, and a NS5A inhibitor in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.